Saturated Spectroscopy and Unsaturated Spectroscopy, Respectively
Total Page:16
File Type:pdf, Size:1020Kb
Clinical Group Imaging Journal of Clinical and Medical Sciences DOI http://doi.org/10.17352/2455-8702.000036 ISSN: 2455-8702 DOI CC By Alireza Heidari* Clinical Image Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA Saturated Spectroscopy and Unsaturated Received: 11 January, 2018 Accepted: 12 February, 2018 Published: 15 February, 2018 Spectroscopy Comparative Study on *Corresponding author: Alireza Heidari, Faculty of Chemistry, California South University, 14731 Comet Malignant and Benign Human Cancer St. Irvine, CA 92604, USA, E-mail: Cells and Tissues with the Passage of https://www.peertechz.com Time under Synchrotron Radiation Image Article In the current study, we have experimentally and comparatively investigated and compared malignant human cancer cells and tissues before and after irradiating of synchrotron radiation using Saturated Spectroscopy and Unsaturated Spectroscopy, respectively. It is clear that malignant human cancer cells and tissues have gradually transformed to benign human cancer cells and tissues under synchrotron radiation with the passage of time (Figures 1,2) [1–163]. It should be noted that malignant human cancer cells and tissues were exposed under white synchrotron radiation for 30 days. Furthermore, there is a shift of the spectrum in Figure 2: Unsaturated Spectroscopy analysis of malignant human cancer all of spectra after irradiating of synchrotron radiation that cells and tissues. (a) before and (b) after irradiating of synchrotron radiation in transformation process to benign human cancer cells and tissues with the it is because of the malignant human cancer cells and tissues passage of time [1–163]. shrink post white synchrotron irradiation with the passage of time. In addition, all of the fi gures are related to the same human cancer cells and tissues. Moreover, in all of the fi gures y–axis shows intensity and also x–axis shows energy (keV). It can be concluded that malignant human cancer cells and tissues have gradually transformed to benign human cancer cells and tissues under synchrotron radiation with the passage of time (Figures 1,2) [1–163]. References 1. Bastogne T (2017) Quality-by-design of nanopharmaceuticals – a state of the art, Nanomedicine: Nanotechnology. Biology and Medicine, 2017. Link: https://goo.gl/AsXAPM 2. Željka Vanić, Nataša Škalko-Basnet (2013) Nanopharmaceuticals for improved topical vaginal therapy: Can they deliver? European Journal of Pharmaceutical Sciences 50: 29-41. Link: https://goo.gl/YHnrKS 3. German A. Islan, Marcela Durán, Maximiliano L. Cacicedo, Gerson Nakazato, Figure 1: Saturated Spectroscopy analysis of malignant human cancer cells Renata K.T. Kobayashi, Diego S.T. Martinez, Guillermo R. Castro, Nelson and tissues. (a) before and (b) after irradiating of synchrotron radiation in Durán (2017) Nanopharmaceuticals as a solution to neglected diseases: Is it transformation process to benign human cancer cells and tissues with the possible? Acta Tropica 170: 16-42. Link: https://goo.gl/w3yud3 passage of time [1–163]. 001 Citation: Heidari A (2018) Saturated Spectroscopy and Unsaturated Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation. Imaging J Clin Medical Sci 5(1): 001-007. DOI: http://doi.org/10.17352/2455-8702.000036 4. Willie E. Bawarski, Elena Chidlowsky, Dhruba J. Bharali, Shaker A. Mousa 19. Cristina Gabellieri, Heico Frima (2011) Nanomedicine in the European (2008) Emerging nanopharmaceuticals, Nanomedicine: Nanotechnology. Commission policy for nanotechnology, Nanomedicine: Nanotechnology. Biology and Medicine 4: 273-282. Link: https://goo.gl/ppWH2w Biology and Medicine 7: 519-520. Link: https://goo.gl/AmiHK4 5. Michael A.W. Eaton (2011) How do we develop nanopharmaceuticals under 20. Robert M. Frederickson, SM Moghimi, E Wagner, Seppo Yla-Herttuala open innovation?, Nanomedicine: Nanotechnology, Biology and Medicine 7: (2016) Call for papers: Nanoparticle Development and Applications in 371-375. Link: https://goo.gl/q22oy8 Cellular and Molecular Therapies. Molecular Therapy 24: 1334-1335. Link: https://goo.gl/X7nPqz 6. Kunn Hadinoto, Yue Yang (2014) Continuous and sustainable granulation of nanopharmaceuticals by spray coagulation encapsulation in 21. Mehrdad Namdari, Ali Eatemadi, Maryam Soleimaninejad, Aiyelabegan T. alginate. International Journal of Pharmaceutics 473: 644-652. Link: Hammed (2017) A brief review on the application of nanoparticle enclosed https://goo.gl/GMZ8tU herbal medicine for the treatment of infective endocarditis. Biomedicine & Pharmacotherapy 87: 321-331. Link: https://goo.gl/Ufi 6xb 7. Sonke Svenson, Marc Wolfgang, Jungyeon Hwang, John Ryan, Scott Eliasof (2011) Preclinical to clinical development of the novel camptothecin 22. Tie Yi Kiew, Wean Sin Cheow, Kunn Hadinoto (2015) Preserving the nanopharmaceutical CRLX101. Journal of Controlled Release 153: 49-55. supersaturation generation capability of amorphous drug-polysaccharide Link: https://goo.gl/yPsX1U nanoparticle complex after freeze drying. International Journal of Pharmaceutics 484: 115-123. Link: https://goo.gl/tyK6AP 8. Sosnik A (XXX) Reversal of multidrug resistance by the inhibition of ATP- binding cassette pumps employing Generally Recognized As Safe (GRAS) 23. S. Moein Moghimi, Peter P. Wibroe, Shen Y. Helvig, Z. Shadi Farhangrazi, nanopharmaceuticals: A review. Advanced Drug Delivery Reviews 65: 1828- A (2012) Christy Hunter, Genomic perspectives in inter-individual adverse 1851. Link: https://goo.gl/W9P8tn responses following nanomedicine administration: The way forward. Advanced Drug Delivery Reviews 64: 1385-1393. Link: https://goo.gl/RE6h1D 9. Jelena Filipović-Grčić, Aleš Mrhar, Hans Junginger (2013) Thematic Issue on Emerging nanopharmaceuticals for nonparenteral application 24. Pilar Rivera Gil, Dominik Hühn, Loretta L. del Mercato, Daniel Sasse, Wolfgang routes, European Journal of Pharmaceutical Sciences 5: 1. Link: J. Parak (2010) Nanopharmacy: Inorganic nanoscale devices as vectors https://goo.gl/sQtA4P and active compounds. Pharmacological Research 62: 115-125. Link: https://goo.gl/bKn2uU 10. Yu H, Hadinoto K (2015) Mitigating the adverse effect of spray drying on the 25. Beverly A. Rzigalinski, Jeannine S. Strobl (2009) Cadmium-containing supersaturation generation capability of amorphous nanopharmaceutical nanoparticles: Perspectives on pharmacology and toxicology of quantum powders. Powder Technology 277: 97-104. Link: https://goo.gl/C4cKYU dots. Toxicology and Applied Pharmacology 238: 280-288. Link: 11. S. Moein Moghimi, Z. Shadi Farhangrazi (2013) Nanomedicine and the https://goo.gl/ZYfVUb complement paradigm, Nanomedicine: Nanotechnology. Biology and 26. Valerie E. Fako, Darin Y. Furgeson (2009) Zebrafi sh as a correlative and Medicine 9: 458-460. Link: https://goo.gl/1QDsXJ predictive model for assessing biomaterial nanotoxicity. Advanced Drug 12. S. Eliasof, P.S. Ng, P. Lim Soo, J. Podobinski, R.I. Case, P. Shum, J.G. Martinez, Delivery Reviews 61: 478-486. Link: https://goo.gl/DDYYt7 S.R. Kabir, D. Lazarus, S. Svenson (2010) 425 Signifi cantly enhanced 27. Vanessa Sainz, João Conniot, Ana I. Matos, Carina Peres, Eva Zupan-i-, therapeutic profi le of docetaxel in novel nanopharmaceutical CRLX288. Liane Moura, Liana C. Silva, Helena F. Florindo, Rogério S. Gaspar (2015) European Journal of Cancer Supplements. 8: 135. R e gulatory aspects on nanomedicines. Biochemical and Biophysical Research Communications 468: 504-510. Link: https://goo.gl/oVy5qE 13. Concepción Domingo, Javier Saurina (2012) An overview of the analytical characterization of nanostructured drug delivery systems: Towards green 28. Ruth Duncan, María J. Vicent (2010) D o HPMA copolymer conjugates have and sustainable pharmaceuticals: A review. Analytica Chimica Acta 744: a future as clinically useful nanomedicines? A critical overview of current 8-22. Link: https://goo.gl/ZTsGLS status and future opportunities. Advanced Drug Delivery Reviews 62: 272- 282. Link: https://goo.gl/rtVtcw 14. Asmita Samadder, Suresh K. Abraham, Anisur Rahman Khuda-Bukhsh (2016) Nanopharmaceutical approach using pelargonidin towards enhancement 29. Xing Zhou, Ling Che, Yanling Wei, Yin Dou, Sha Chen, Hongmei He, Hao Gong, of effi cacy for prevention of alloxan-induced DNA damage in L6 cells via Xiaohui Li, Jianxiang Zhang (2014) Fa cile route to versatile nanoplatforms activation of PARP and p53. Environmental Toxicology and Pharmacology for drug delivery by one-pot self-assembly. Acta Biomaterialia 10: 2630-2642. 43: 27-37. Link: https://goo.gl/95Bvwu Link: https://goo.gl/FwuV7q 15. Y. Yen, T. Synold, G.J. Weiss, T. Schluep, J. Ryan (2010) 423 Phase 1 dose 30. Heidari A (2016), Christopher Brown (2015) Study of Composition and escalation, safety and pharmacokinetic study of IT-101 (CRLX101), a novel Morphology of Cadmium Oxide (CdO) Nanoparticles for Eliminating Cancer nanopharmaceutical containing camptothecin, in advanced solid tumor Cells. Journal of Nanomedicine Research 2: 20. Link: https://goo.gl/Rtcgj9 cancer patients. European Journal of Cancer Supplements. 8: 134-135. Link: https://goo.gl/M5yzmk 31. Heidari A (2016) Christopher Brown (2015) Study of Surface Morphological, Phytochemical and Structural Characteristics of Rhodium (III) Oxide (Rh2O3) 16. Intan DM. Azmi, Peter P. Wibroe, Lin-Ping Wu, Ali I. Kazem, Heinz Amenitsch, Nanoparticles. International Journal of Pharmacology, Phytochemistry and Seyed M. Moghimi, Anan Yaghmur (2016) A structurally